ALK and lung carcinoma: More recently, following the results of the phase 3 trial—ALK in lung cancer trial of brigatinib in 1st line (ALTA-1L)—brigatinib was granted marketing authorization for the first-line treatment of advanced ALK+ NSCLCs [7,8,9,10].